KRAS and neoplasm: The intracellular KRAS mutations generate neoantigens presented in the context of HLA‐A*11:01, ‐A*0301, ‐C*0802, etc.[27, 28] Of note, KRAS mutations can also be presented by HLA class II alleles.[29] Previously, our group and others have identified TCRs capable of specifically recognizing KRAS‐G12V peptides presented by HLA‐A11:01, inducing cytotoxic T cell responses against tumor cells with KRAS‐G12V mutations.[30, 31, 32]